PMID- 37564007
OWN - NLM
STAT- Publisher
LR  - 20230811
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2023 Aug 11
TI  - Mineralocorticoid replacement therapy in salt-wasting congenital adrenal 
      hyperplasia.
LID - 10.1111/cen.14959 [doi]
AB  - Patients with salt-wasting congenital adrenal hyperplasia (SW-CAH) usually show 
      pronounced impairment of aldosterone secretion and, therefore, also require 
      mineralocorticoid replacement. While a lot of research and discussion focusses on 
      the glucocorticoid therapy in SW-CAH to replace the missing cortisol and to 
      control adrenal androgen excess, very little research is dealing with 
      mineralocorticoid replacement. However, recent data demonstrated an increased 
      cardiovascular risk in adult CAH patients urging to reflect also on the current 
      mineralocorticoid replacement therapy. In this review, we explain the role and 
      function of the mineralocorticoid receptor, its ligands and inhibitors and its 
      relevance for the therapy of patients with SW-CAH. We performed an extensive 
      literature search and present data on mineralocorticoid therapy in SW-CAH 
      patients as well as clinical advice how to monitor and optimise mineralocorticoid 
      replacement therapy.
CI  - (c) 2023 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
FAU - Lang, Katharina
AU  - Lang K
AD  - Endocrinology in Charlottenburg, Berlin, Germany.
FAU - Quinkler, Marcus
AU  - Quinkler M
AUID- ORCID: 0000-0003-4028-1671
AD  - Endocrinology in Charlottenburg, Berlin, Germany.
AD  - Department of Endocrinology and Metabolism, Charite-Universitatsmedizin, Campus 
      Mitte, Berlin, Germany.
FAU - Kienitz, Tina
AU  - Kienitz T
AD  - Endocrinology in Charlottenburg, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230811
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
SB  - IM
OTO - NOTNLM
OT  - 17-hydroxy-progesterone
OT  - adrenal insufficiency
OT  - androstenedione
OT  - fludrocortisone
OT  - hydrocortisone
EDAT- 2023/08/11 06:43
MHDA- 2023/08/11 06:43
CRDT- 2023/08/11 03:31
PHST- 2023/07/31 00:00 [revised]
PHST- 2023/05/21 00:00 [received]
PHST- 2023/08/03 00:00 [accepted]
PHST- 2023/08/11 06:43 [medline]
PHST- 2023/08/11 06:43 [pubmed]
PHST- 2023/08/11 03:31 [entrez]
AID - 10.1111/cen.14959 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2023 Aug 11. doi: 10.1111/cen.14959.